News >

European Panel Recommends Against Neratinib for HER2-Positive Breast Cancer

Jason Harris
Published: Friday, Feb 23, 2018

breast cancer
European regulators have recommended against approving a marketing authorization application (MAA) for the use of neratinib (Nerlynx) as extended adjuvant treatment for women with early stage HER2-positive breast cancer.

The rate of dose reductions (7.3% vs 26.4%) and holds (14.6% vs 33.9%) due to diarrhea were lower in the patients who received loperamide. However, the rate of discontinuation due to diarrhea was higher in the loperamide cohort at 20.4% versus 16.8% with neratinib alone.


  1. Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18:1688-700.
  2. Puma Biotechnology presents interim results of phase II CONTROL Trial of PB272 in extended adjuvant treatment of her2-positive early stage breast cancer at the 2017 AACR Annual Meeting. Posted April 4, 2017. Accessed February 23, 2018.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication